natgillin/translations-raw huggingface dataset:
In pigs, Metacam is used in non-infectious locomotor disorders (diseases that affect the ability to move) to reduce the symptoms of lameness and inflammation, for the relief of post-operative pain associated with minor soft tissue surgery such as castration, and for supportive therapy together with appropriate antibiotic therapy in the treatment of diseases that occur after farrowing (giving birth) such as puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome, a bacterial infection of the udder and/or the womb).
Metacam se koristi kod svinja u slučaju nezaraznih lokomotornih poremećaja (bolesti koja zahvaća sposobnost kretanja) u svrhu smanjenja simptoma hromosti i upale, za ublažavanje postoperativne boli povezane s manjim kirurškim zahvatima u mekanom tkivu poput kastracije, te za potrebe potporne terapije zajedno s odgovarajućom antibiotskom terapijom u svrhu liječenja bolesti koje mogu nastupiti nakon prašenja (nakon poroda) poput puerperalne septikemije i toksemije (sindroma mastis-metritis- agalaktia, odnosno bakterijske infekcije vimena i/ili maternice).
In pigs, Rheumocam is used in non-infectious locomotor disorders (diseases that affect the ability to move) to reduce the symptoms of lameness and inflammation, for the relief of post-operative pain associated with minor soft tissue surgery such as castration, and for supportive therapy together with appropriate antibiotic therapy in the treatment of diseases that occur after farrowing (giving birth)
Rheumocam se koristi kod svinja u slučaju nezaraznih lokomotornih poremećaja (bolesti koja zahvaća sposobnost kretanja) u svrhu smanjenja simptoma hromosti i upale, za ublažavanje postoperativne boli povezane s manjim kirurškim zahvatima u mekanom tkivu poput kastracije, te za potrebe potporne terapije zajedno s odgovarajućom antibiotskom terapijom u svrhu liječenja bolesti koje mogu nastupiti nakon prašenja (nakon poroda) poput puerperalne septikemije i toksemije (sindroma mastis
In pigs, serious adverse drug reactions following the use of Econor are mainly associated with breeds and cross breeds of Danish and/or Swedish Landrace.
Kod svinja su ozbiljne nuspojave na lijek nakon upotrebe Econora uglavnom bile povezane s pasminama i hibridima danskog i/ili švedskog landrasa.
In pigs, the efficacy of Econor in the claimed indications was investigated in challenge studies (i.e. pigs were artificially infected with the bacteria) or in field studies (i.e. natural infections under farm conditions).
U svinja je djelotvornost Econora u navedenim indikacijama ispitana u studijama izazova (tj. svinjama su umjetno ubrizgane bakterije) ili u terenskim studijama (tj. prirodne infekcije u uvjetima na farmi).
In pigs, the pharmacokinetic profile of tulathromycin when administered as a single intramuscular dose of 2.5 mg/kg bodyweight, was also characterised by rapid and extensive absorption followed by high distribution and slow elimination.
Kada je tulatromicin bio primijenjen na svinjama kao pojedinačna intramuskularna doza od 2,5 mg/kg tjelesne težine, njegov je farmakokinetički profil također bio karakteriziran vrlo brzom i ekstenzivnom apsorpcijom nakon koje je uslijedila visoka distribucija i spora eliminacija.
In pigs, the pharmacokinetic profile of tulathromycin when administered as a single intramuscular dose of 2.5 mg/kg bodyweight, was also characterised by rapid and extensive absorption followed by high distribution and slow elimination.
Kada je tulatromicin primijenjen na svinjama kao pojedinačna intramuskularna doza od 2,5 mg/kg tjelesne težine, njegov je farmakokinetički profil također bio karakteriziran vrlo brzom i ekstenzivnom apsorpcijom nakon koje je uslijedila visoka distribucija i spora eliminacija.
In pigs, the pharmacokinetic profile of tulathromycin when administered as a single intramuscular dose of 2.5 mg/kg bodyweight, was also characterised by rapid and extensive absorption followed by high distribution and slow elimination.
Kada je tulatromicin primijenjen na svinjama kao pojedinačna intramuskularna doza od 2,5 mg/kg tjelesne težine, njegov je farmakokinetički profil također karakteriziran vrlo brzom i ekstenzivnom apsorpcijom nakon koje je uslijedila visoka distribucija i spora eliminacija.
In pivotal clinical studies supporting the use of Mozobil, all patients received daily morning doses of 10 g/kg G-CSF for 4 consecutive days prior to the first dose of plerixafor and on each morning prior to apheresis.
U pivotalnim kliničkim ispitivanjima lijeka Mozobil svi su bolesnici primali jutarnju dozu G-CSF-a od 10 µg/kg tijekom 4 uzastopna dana prije primjene prve doze pleriksafora i svako jutro prije afereze.
In pivotal phase III clinical trials the following medicinal products were routinely combined with ivabradine with no evidence of safety concerns: angiotensin converting enzyme inhibitors, angiotensin II antagonists, beta-blockers, diuretics, anti-aldosterone agents, short and long acting nitrates, HMG CoA reductase inhibitors, fibrates, proton pump inhibitors, oral antidiabetics, aspirin and other anti- platelet medicinal products.
U kliničkim ispitivanjima faze III, slijedeći lijekovi su rutinski primjenjivani s ivabradinom bez štetnih utjecaja: inhibitori konvertaze angiotenzina, antagonisti angiotenzina II, diuretici, nitrati brzog i dugog djelovanja, inhibitori HMG CoA reduktaze, fibrati, blokatori protonske pumpe, oralni antidijabetici, aspirin i antikoagulansi.
In pivotal studies conducted in patients undergoing PCI, events of acute renal failure (0.1%), renal failure (0.1%) and increased serum creatinine (0.2%) were reported to occur after administration of cangrelor in clinical trials.
U pivotalnim ispitivanjima provedenima u bolesnika podvrgnutih PCI, prijavljeni su događaji akutnog zatajenja bubrega (0,1%), zatajenja bubrega (0,1%) i porasta kreatinina u serumu (0,2%) nakon primjene kangrelora u kliničkim ispitivanjima.
In pJIA patients, the central volume of distribution was 50 ml/kg, the peripheral volume of distribution was 53 ml/kg, resulting in a volume of distribution at steady state of 103 ml/kg.
Kod bolesnika s pJIA središnji volumen distribucije iznosio je 50 ml/kg, a periferni volumen distribucije 53 ml/kg, što je rezultiralo volumenom distribucije u stanju dinamičke ravnoteže od
In PKU treatment, a main study compared the reductions in blood phenylalanine in 88 patients treated with either Kuvan or placebo (a dummy treatment).
U liječenju PKU, glavnom ispitivanju koje je usporedilo smanjenje fenilalanina u krvi u 88 bolesnika liječenih s lijekom Kuvan ili pod placebom (prividno liječenje).
In PKU, it works by enhancing the activity of the defective enzyme, while in BH4 deficiency it replaces the missing cofactor.
U slučaju PKU, lijek djeluje tako što povećava aktivnost defektnog enzima, a u slučaju nedostatka BH4 zamjenjuje kofaktor koji nedostaje.
In placebo controlled clinical trials of 12 weeks duration mean reduction in systolic and diastolic blood pressures from base line to end of treatment were 3mm Hg and 4.2 mm Hg respectively.
12-tjednim placebom kontroliranim kliničkim ispitivanjima, srednja vrijednost smanjenja sistoličkog odnosno dijastoličkog krvnog tlaka od početnih vrijednosti pa do kraja terapije bila je 3 mmHg odnosno 4,2 mmHg.
In placebo controlled studies low antibody responses have been reported with a frequency (3.4%) similar to that of placebo (4.8%).
U ispitivanjima kontroliranima placebom, nizak odgovor protutijela zabilježen je učestalošću (3,4%) sličnoj onoj za placebo (4,8%).
In placebo controlled trials in a post-operative ICU population previously intubated and sedated with midazolam or propofol, Dexdor significantly reduced the requirement for both rescue sedative (midazolam or propofol) and opioids during sedation for up to 24 hours.
U placebom kontroliranim ispitivanjima na bolesnicima koji se nakon operacije nalaze u jedinici intenzivnog liječenja, a koji su ranije bili intubirani i sedirani midazolamom ili propofolom, Dexdor je značajno smanjio potrebe i za dodatnim sedativima (midazolam ili propofol) i za opioidima za vrijeme sedacije sve do 24 sata.
In placebo- controlled studies, more than 1800 patients were treated with the therapeutic dose of either 2.5 mg linagliptin twice daily (or its bioequivalent of 5 mg linagliptin once daily) in combination with metformin for ≥ 12/24 weeks.
U placebom kontroliranim ispitivanjima više od 1800 bolesnika bilo je liječeno terapijskom dozom od 2,5 mg linagliptina dvaput dnevno (ili njegovim bioekvivalentom od 5 mg linagliptina jedanput dnevno) u kombinaciji s metforminom u trajanju ≥ 12/24 tjedna.
In placebo-controlled clinical trials with abatacept, adverse reactions (ARs) were reported in 51.8% of abatacept-treated patients and 46.4% of placebo-treated patients.
U placebom kontroliranim kliničkim ispitivanjima abatacepta nuspojave su prijavljene u 51,8% bolesnika liječenih abataceptom i 46,4% bolesnika koji su primali placebo.
In placebo-controlled clinical trials with naltrexone / bupropion for the treatment of obesity in adult subjects, no suicides or suicide attempts were reported in studies up to 56 weeks duration with naltrexone / bupropion, and suicidal ideation was not more commonly reported in subjects treated with naltrexone / bupropion compared to placebo.
U placebom kontroliranim kliničkim ispitivanjima s naltrekson / bupropionom za liječenje pretilosti u odraslih ispitanika, nisu zabilježena samoubojstva ili pokušaji samoubojstva u ispitivanjima do 56 tjedana s naltrekson / bupropionom, a suicidalne ideje nisu češće prijavljene u ispitanika liječenih naltrekson / bupropionom u odnosu na placebo.
In placebo-controlled clinical trials, malignancies were reported in 29 of 2,111 abatacept-treated patients observed during 1,829 patient-years, and in 12 of 1,099 placebo-treated patients observed during 849 patient-years.
U placebom kontroliranim kliničkim ispitivanjima zloćudne su bolesti prijavljene u 29 od 2111 bolesnika liječenih abataceptom, praćenih tijekom 1829 bolesnik-godina, te u 12 od 1099 bolesnika koji su primali placebo, praćenih tijekom 849 bolesnik-godina.
In placebo-controlled RA studies with Kineret, treatment was associated with small reductions in the mean values for total white blood count and absolute neutrophil count (ANC).
U placebom kontroliranim kliničkim ispitivanjima u bolesnika s RA liječenje Kineretom bilo je povezano s malim sniženjem prosječnih vrijednosti za ukupni broj leukocita i apsolutni broj neutrofila (ABN).
In placebo-controlled studies (studies 1 and 2), the incidence of transaminase elevations (>3 x upper limit of normal [ULN]) were similar between subjects in the ivacaftor and placebo treatment groups (see section 4.8).
U placebom kontroliranim ispitivanjima (ispitivanja 1 i 2), incidencija povišenih transaminaza (> 3 puta iznad gornje granice normale [GGN]) bila je slična u ispitanika liječenih ivakaftorom i onih koji su primali placebo (vidjeti dio 4.8).
In placebo-controlled studies in RA patients, the most frequently reported adverse reactions with Kineret were injection site reactions (ISRs), which were mild to moderate in the majority of patients.
U placebom kontroliranim ispitivanjima s bolesnicima s RA najčešće prijavljene nuspojave s Kineretom bile su reakcije na mjestu primjene (ISR), koje su bile blage do umjerene u većine bolesnika.
In placebo-controlled studies in RA patients, the most frequently reported adverse reactions with Kineret were injection site reactions (ISRs), which were mild to moderate in the majority of patients.
U placebom kontroliranim ispitivanjima u bolesnika s RA, najčešće prijavljene nuspojave s Kineretom bile su reakcije na mjestu primjene (ISRs), koje su bile blage do umjerene u većine bolesnika.
In placebo-controlled studies involving 1,842 adult patients with partial-onset seizures (1,282 patients treated with eslicarbazepine acetate and 560 treated with placebo), 50.7% of patients treated with eslicarbazepine acetate and 27.7% of patients treated with placebo experienced adverse reactions.
U placebom -kontroliranim studijama koje uključuju 1842 odrasla bolesnika s parcijalnim napadajima (1282 bolesnika liječenih eslikarbazepinacetatom i 560 liječenih placebom), kod 50,7% bolesnika liječenih eslikarbazepinacetatom i 27,7% bolesnika liječenih placebom nastupile su nuspojave.
In placebo-controlled studies involving 1,842 adult patients with partial-onset seizures (1,282 patients treated with eslicarbazepine acetate and 560 treated with placebo), 50.7% of patients treated with eslicarbazepine acetate and 27.7% of patients treated with placebo experienced adverse reactions.
U placebom-kontroliranim studijama koje uključuju 1842 odrasla bolesnika sparcijalnim napadajima (1282 bolesnika liječenih eslikarbazepinacetatom i 560 liječenih placebom), kod 50,7% bolesnika liječenih eslikarbazepinacetatom i 27,7% bolesnika liječenih placebom nastupile su nuspojave.
In placebo-controlled studies involving 1,842 adult patients with partial-onset seizures (1,282) patients treated with eslicarbazepine acetate and 560 treated with placebo), 50.7% of patients treated with eslicarbazepine acetate and 27.7% of patients treated with placebo experienced adverse reactions.
U placebom kontroliranim studijama koje uključuju 1842 odrasla bolesnika s parcijalnim napadajima (1282 bolesnika liječenih eslikarbazepinacetatom i 560 liječenih placebom), kod 50,7% bolesnika liječenih eslikarbazepinacetatom i 27,7% bolesnika liječenih placebom nastupile su nuspojave.
In placebo-controlled studies involving 1.842 adult patients with partial-onset seizures (1,282 patients treated with eslicarbazepine acetate and 560 treated with placebo), 50.7% of patients treated with eslicarbazepine acetate and 27.7% of patients treated with placebo experienced adverse reactions.
U placebom -kontroliranim studijama koje uključuju 1842 odrasla bolesnika s parcijalnim napadajima (1282 bolesnika liječenih eslikarbazepinacetatom i 560 liječenih placebom), kod 50,7% bolesnika liječenih eslikarbazepinacetatom i 27,7% bolesnika liječenih placebom nastupile su nuspojave.
In placebo-controlled studies palpitations were reported >1% more often in the teriflunomide 7 mg group (but not in the teriflunomide 14 mg group) when compared to placebo.
U placebom kontroliranim ispitivanjima palpitacije su bile prijavljene >1% češće u skupini koja je primala 7 mg teriflunomida (ali ne i u skupini koja je primala 14 mg teriflunomida) u usporedbi sa skupinom koja je primala placebo.
In placebo-controlled studies the following was established: systolic blood pressure was >140 mm Hg in 19.9% of patients receiving 14 mg/day teriflunomide as compared to 15.5% receiving placebo; systolic blood pressure was >160 mm Hg in 3.8% of patients receiving 14 mg/day teriflunomide as compared to 2.0% receiving placebo; diastolic blood pressure was >90 mm Hg in 21.4% of patients receiving 14 mg/day teriflunomide as compared to 13.6% receiving placebo.
Tijekom placebom kontroliranih ispitivanja utvrđeno je sljedeće: sistolički krvni tlak bio je >140 mm Hg u 19,9% bolesnika koji su primali teriflunomid u dozi od 14 mg/dan u usporedbi sa 15,5% bolesnika koji su primali placebo; sistolički krvni tlak bio je >160 mm Hg u 3,8% bolesnika koji su primali teriflunomid u dozi od 14 mg/dan u usporedbi s 2,0% bolesnika koji su primali placebo; dijastolički krvni tlak bio je >90 mm Hg u 21,4% bolesnika koji su primali teriflunomid u dozi od 14 mg/dan u usporedbi sa 13,6% bolesnika koji su primali placebo;
In placebo-controlled studies with Kineret, treatment was associated with small reductions in the mean values for total white blood count and absolute neutrophil count (ANC).
U placebom kontroliranim kliničkim ispitivanjima liječenje Kineretom bilo je povezano s malim sniženjem prosječnih vrijednosti za ukupni broj leukocita i apsolutni broj neutrofila (ABN).
In placebo-controlled studies, bosentan-related decreases in haemoglobin concentration were not progressive, and stabilised after the first 4–12 weeks of treatment.
U placebom kontroliranim studijama smanjenje koncentracije hemoglobina uzrokovano bosentanom nije bilo progresivno te se ustalilo nakon prvih 4–12 tjedana liječenja.
In placebo-controlled studies, elevations of hepatic transaminases were observed.
Proučavane su povišene jetrene transaminaze u placebom kontroliranim ispitivanjima.
In placebo-controlled studies, in total there have been 17 cases of peripheral neuropathy that were confirmed by nerve conduction studies, out of 898 patients treated.
U placebom kontroliranim ispitivanjima bilo je ukupno 17 slučajeva periferne neuropatije od 898 liječenih bolesnika, što je potvrđeno ispitivanjima provodljivosti živaca.
In placebo-controlled studies, macitentan-related decreases in haemoglobin concentration were not progressive, stabilised after the first 4–12 weeks of treatment and remained stable during chronic treatment.
U placebom kontroliranim ispitivanjima, s macitentanom povezani padovi koncentracije hemoglobina nisu bili progresivni te su se stabilizirali nakon prvih 4 do 12 tjedana liječenja i ostali su stabilni tijekom kroničnog liječenja.
In placebo-controlled studies, the incidence of proteinuria was higher in patients treated with Tecfidera (9%) compared to placebo (7%).
U placebom kontroliranim ispitivanjima incidencija proteinurije je bila viša u bolesnika liječenih Tecfiderom (9%) u usporedbi s placebom (7%).
In placebo-controlled trials in patients with hypertension, the overall incidence of adverse events did not differ between the irbesartan (56.2 %) and the placebo groups (56.5 %).
U placebom kontroliranim ispitivanjima, koja su provedena na bolesnicima s hipertenzijom, ukupna incidencija štetnih događaja nije se razlikovala između skupine koja je uzimala irbesartan (56,2%) i placebo skupine (56,5%).
In placebo-controlled trials in patients with hypertension, the overall incidence of adverse events did not differ between the irbesartan (56.2 %) and the placebo groups (56.5 %).
U placebom kontroliranim kliničkim ispitivanjima, koja su provedena na bolesnicima s hipertenzijom, ukupna incidencija štetnih događaja nije se razlikovala između skupine koja je uzimala irbesartan (56,2%) i placebo skupine (56,5%).
In plaque psoriasis, infiltration by inflammatory cells, including T-cells, leads to increased TNF levels in psoriatic lesions compared with levels in uninvolved skin.
Kod plak psorijaze infiltracija upalnim stanicama, uključujući i T stanice, vodi do porasta razine TNF- a u psorijatičnim lezijama u usporedbi s razinama istih u koži koja nije zahvaćena bolešću.
In plasma samples collected up to 24 hours after administration, lenvatinib constituted 97% of the radioactivity in plasma radiochromatograms while the M2 metabolite accounted for an additional 2.5%.
U uzorcima plazme prikupljenima do 24 sata nakon primjene, lenvatinib je činio 97% radioaktivnosti u radiokromatogramima plazme, dok je metabolit M2 činio dodatnih 2,5%.
In plasma, both brinzolamide and N- desethylbrinzolamide concentrations are low and generally below assay quantitation limits (<7.5 ng/ml).
U plazmi su koncentracije i brinzolamida i N-desetil- brinzolamida niske i općenito su ispod limita testa za određivanje (<7,5 ng/ml ).
In plasma, metabolites M-1 and M-2 were detected only at trace concentrations and metabolite M-5, the more abundant metabolite, accounted for a total of 6.5% relative to parent compound.
U plazmi, metaboliti M-1 i M-2 bili su otkriveni samo u tragovima, a metabolit M-5, obilnije prisutan, činio je ukupno 6,5% u odnosu na prekursor.
In plasma, olanzapine is bound to albumin and α1-acid glycoprotein.
Olanzapin se u plazmi veže na albumin i na α1- kiseli-glikoprotein.
In plasma, tacrolimus is highly bound (> 98.8%) to plasma proteins, mainly to serum albumin and α-1-acid glycoprotein.
U plazmi je takrolimus u visokom postotku vezan (> 98,8%) za proteine plazme, uglavnom za serumski albumin i α-1-kiseli glikoprotein.
In plasma, tacrolimus is highly bound (> 98.8%) to plasma proteins, mainly to serum albumin and α-1-acid glycoprotein.
U plazmi je takrolimus uglavnom vezan (> 98,8%) za proteine plazme, uglavnom za serumski albumin i α-1-kiseli glikoprotein.
In plasma, the principal circulating compound is the metabolite M1.
Glavni cirkulirajući metabolit u plazmi je M1.
In plasma, the relative exposures of the S- and R- enantiomers of lenalidomide are approximately 56% and 44%, respectively.
U plazmi, relativne izloženosti S- i R- enantiomera lenalidomida iznose približno 56% odnosno 44%.
In plasma, unchanged thalidomide represents 80% of the circulatory components.
U plazmi, nepromijenjeni talidomid predstavlja 80% cirkulirajućih komponenti.
In plastic box: Lyophilisate: vial (glass) and Solvent: vial (glass)
U plastičnoj kutiji: Liofilizat: bočica (staklena) i Otapalo: bočica (staklena)
In PNH patients, pharmacodynamic activity correlates directly with eculizumab serum concentrations and maintenance of trough levels above  35 microgram/ml results in essentially complete blockade of haemolytic activity in the majority of PNH patients.
U bolesnika s PNH-om farmakodinamička aktivnost izravno korelira s koncentracijama ekulizumaba u serumu i održavanje najnižih razina iznad 35 mikrograma/ml rezultira u biti potpunom blokadom hemolitičke aktivnosti u većine bolesnika s PNH-om.
In PNH patients, uncontrolled terminal complement activation and the resulting complement- mediated intravascular haemolysis are blocked with Soliris treatment.
U bolesnika s PNH-om, liječenje lijekom Soliris blokira nekontroliranu aktivaciju terminalnih komponenti komplementa i posljedičnu intravaskularnu hemolizu posredovanu komplementom.
In PNH, chronic administration of Soliris resulted in a rapid and sustained reduction in complement- mediated haemolytic activity.
Kod PNH-a, kronična primjena lijeka Soliris rezultirala je brzim i trajnim smanjenjem hemolitičke aktivnosti posredovane komplementom.
In PNH, treatment for patients aged 18 and over consists of an infusion (drip into a vein) of 600 mg over 25 to 45 minutes once a week, followed by 900 mg in the fifth week.
U slučaju PNH-a, liječenje bolesnika u dobi od 18 godina i starijih sastoji se od infuzije (dripa u venu) od 600 mg tijekom 25 do 45 minuta jednom tjedno, nakon čega slijedi 900 mg u petom tjednu.
In polyarticular juvenile idiopathic arthritis, around 40% of patients aged between 4 and 17 years receiving Humira, either alone or in combination with methotrexate, had a flare-up of arthritis, compared with around 69% of those receiving placebo.
Kod poliartikularnog juvenilnog idiopatskog artritisa oko 40 % bolesnika u dobi od 4 do 17 godina koji su primali lijek Humira kao monoterapiju ili u kombinaciji s metotreksatom, osjetilo je pogoršanje artritisa u usporedbi s oko 69 % onih koji su primali placebo.
In polyarticular juvenile idiopathic arthritis, it took longer for the disease to flare up in the patients continuing to receive Orencia than those who switched to placebo.
U slučaju poliartikularnog juvenilnog idiopatskog artritisa, proteklo je dulje vrijeme do trenutka ponovnog rasplamsavanja bolesti u bolesnika koji su nastavili primati lijek Orencia u odnosu na one kod kojih je zamijenjen placebom.
In polyarticular juvenile idiopathic arthritis, Orencia infusion has been studied in one main study involving patients aged between six and 17 years whose previous treatment had failed.
U slučaju poliartikularnog juvenilnog idiopatskog artritisa, infuzija lijeka Orencia ispitana je u jednom glavnom ispitivanju koje je obuhvatilo bolesnike u dobi između šest i 17 godina čija prethodna terapija nije bila uspješna.
In Pom + LD- Dex treated patients infections led to dose discontinuation in 2.0% of patients, to treatment interruption in 14.3% of patients, and to a dose reduction in 1.3% of patients.
U bolesnika liječenih Pom + LD-Dex, infekcije su dovele obustavljanja terapije u 2,0% bolesnika, do prekida liječenja u 14,3% bolesnika i sniženja doze u 1,3% bolesnika.